EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Excellent Outcomes With High‐Risk Pediatric Hepatoblastoma: A Detailed Analysis of a Large, Single‐Center Experience

Valeria Ripa, Robert S Venick, Samer Ebaid, Noah Federman, Nicole Charland, Caitlin J Thornley, Jonathan Jou iD, Brandon Pearson, Vatche G Agopian, Fady M Kaldas, Suzanne V McDiarmid, Douglas G Farmer

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von Valeria Ripa und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, Transplant Surgery, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Transplantation, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatoblastoma (HBA) is a rare pediatric malignancy treatable with liver transplantation (LTx). Limited data exist on outcomes after LTx for HBA. This study evaluates the therapeutic efficacy of LTx in pediatric patients with HBA, delineates principal complications, and assesses long‐term psychosocial outcomes.

Methods

This retrospective cohort study analyzed a prospectively maintained database of children undergoing LTx for HBA at a single US center from 1984 to 2025. Primary outcomes were patient and graft survival at 1, 5, and 10 years post‐LTx and HBA recurrence. Secondary outcomes included post‐LTx complications, recurrence predictors, and psychosocial parameters.

Results

Of 55 patients (60% female; 40% Hispanic; mean age at diagnosis, 36 months), most had PRETEXT stage III (44%) or IV (47%) disease; mean α‐fetoprotein level at diagnosis was 569 355 ng/mL. All but 1 received chemotherapy; 15 (27%) had pre‐LTx resection. Mean wait time to LTx was 10 months. Pre‐LTx metastatic disease (pulmonary) was present in 5 patients (9%). Explant pathology showed macrovascular invasion ( n = 16), positive lymph nodes ( n = 3), and extra‐hepatic tumor invasion/rupture ( n = 2). Post‐LTx complications included HBA recurrence (20%), hepatic artery thrombosis (11%), and biliary stricture (20%). Patient survival was 89% at 1 year, 74% at 5 and 10 years; graft survival was 89%, 73%, and 73%, respectively. Significant predictors of recurrence were older age at LTx ( p = 0.01), longer waiting time to LTx ( p = 0.02), prior resection ( p = 0.01), larger tumor size ( p = 0.03), vascular invasion ( p = 0.02), and utilization of a segmental graft ( p = 0.002). Mortality was mainly due to recurrence. Psychosocially, 14 patients needed special education, 10 had developmental delays, 5 of 12 adults completed high school, 2 earned college degrees, and 3 are employed.

Conclusion

This large single‐center study demonstrates favorable survival after LTx for high‐risk HBA. Recurrence predictors support avoiding pre‐LTx resection in high‐risk cases. While living donor or split grafts can expedite transplantation, segmental grafts were independently linked to higher recurrence. Notably, metastases at diagnosis did not increase recurrence, supporting aggressive treatment. The rate of HAT and biliary stricture was significantly higher for children transplanted for HBA than for our overall pediatric experience. These findings help guide the management of this rare malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaLiver TransplantationLiver NeoplasmsHumansFemaleChild, PreschoolMaleRetrospective StudiesInfantTreatment OutcomeChildGraft SurvivalRisk FactorsPostoperative ComplicationsNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • University of California, Los Angeles, Transplant Surgery, Los Angeles, California, USA.
  • University of California, Los Angeles, Pediatric Gastroenterology, Los Angeles, California, USA.

ORCID-Profile: Jonathan Jou

Zitieren

APA

Ripa, V., Venick, R. S., Ebaid, S., Federman, N., Charland, N., Thornley, C. J., Jou, J., Pearson, B., Agopian, V. G., Kaldas, F. M., McDiarmid, S. V., & Farmer, D. G. (2026). Excellent Outcomes With High‐Risk Pediatric Hepatoblastoma: A Detailed Analysis of a Large, Single‐Center Experience. Pediatric Transplantation. https://doi.org/10.1111/petr.70354

Vancouver

Ripa V, Venick RS, Ebaid S, Federman N, Charland N, Thornley CJ, et al. Excellent Outcomes With High‐Risk Pediatric Hepatoblastoma: A Detailed Analysis of a Large, Single‐Center Experience. Pediatric Transplantation. 2026. doi:10.1111/petr.70354

BibTeX
@article{Ripa2026,
  author = {Ripa, Valeria and Venick, Robert S and Ebaid, Samer and Federman, Noah and Charland, Nicole and Thornley, Caitlin J and Jou, Jonathan and Pearson, Brandon and Agopian, Vatche G and Kaldas, Fady M and McDiarmid, Suzanne V and Farmer, Douglas G},
  title = {Excellent Outcomes With High‐Risk Pediatric Hepatoblastoma: A Detailed Analysis of a Large, Single‐Center Experience},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70354}
}
Kostenlos starten →